To include your compound in the COVID-19 Resource Center, submit it here.

Santhera sags on FDA delay for Raxone

Santhera Pharmaceuticals Holding AG (SIX:SANN) sank CHF30.85 (37%) to CHF52.65 on Thursday after it said FDA would not support its plan to submit an

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE